miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer

[1]  T. Jiang,et al.  MicroRNA-200c regulates cisplatin resistance by targeting ZEB2 in human gastric cancer cells. , 2017, Oncology reports.

[2]  R. Huang,et al.  The EMT spectrum and therapeutic opportunities , 2017, Molecular oncology.

[3]  X. Bian,et al.  Transcriptional repression of miR-200 family members by Nanog in colon cancer cells induces epithelial-mesenchymal transition (EMT). , 2017, Cancer letters.

[4]  Yonghong Zhu,et al.  Combined treatment with artesunate and bromocriptine has synergistic anticancer effects in pituitary adenoma cell lines , 2017, Oncotarget.

[5]  I. Astsaturov,et al.  Perspectives of HER2-targeting in gastric and esophageal cancer , 2017, Expert opinion on investigational drugs.

[6]  M. Apicella,et al.  Targeted therapies for gastric cancer: failures and hopes from clinical trials , 2017, Oncotarget.

[7]  J. Soh,et al.  Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features , 2017, Scientific Reports.

[8]  A. Tesei,et al.  Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer , 2016, Oncotarget.

[9]  S. Wilks.  Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway. , 2015, Breast.

[10]  M. Cañadas-Garre,et al.  Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer , 2015, Breast Cancer Research and Treatment.

[11]  C. von Buchwald,et al.  Molecular profiling of tumour budding implicates TGFβ‐mediated epithelial–mesenchymal transition as a therapeutic target in oral squamous cell carcinoma , 2015, The Journal of pathology.

[12]  Jingwen Zhang,et al.  Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance , 2015, Scientific Reports.

[13]  P. Malfertheiner,et al.  HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases. , 2015, Human pathology.

[14]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[15]  Tae-Yong Kim,et al.  Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer , 2015, Clinical Cancer Research.

[16]  Wenjin Xi,et al.  MiR‐200c suppresses TGF‐β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer , 2014, International journal of cancer.

[17]  F. López-Ríos,et al.  A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond. , 2014, Cancer letters.

[18]  S. Shimoyama.  Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review). , 2014, Molecular and clinical oncology.

[19]  Wei Liu,et al.  LMO4 inhibits p53-mediated proliferative inhibition of breast cancer cells through interacting p53. , 2012, Life sciences.

[20]  M. Wicha,et al.  Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. , 2012, Molecular cell.

[21]  L. Pecciarini,et al.  HER2 Testing in Gastric Cancer , 2011, Advances in anatomic pathology.

[22]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[23]  A. Rustgi,et al.  The role of the miR-200 family in epithelial-mesenchymal transition , 2010, Cancer biology & therapy.

[24]  M. Shah,et al.  Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[25]  J. T. Jørgensen.  Targeted HER2 Treatment in Advanced Gastric Cancer , 2010, Oncology.

[26]  M. Moasser,et al.  Targeting HER proteins in cancer therapy and the role of the non-target HER3 , 2007, British Journal of Cancer.

[27]  T. Fujita,et al.  PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer , 2006, British Journal of Cancer.

[28]  Ritu Shrestha,et al.  Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma. , 2017, Current cancer drug targets.

[29]  Wei Liu,et al.  The downregulation of miR-200c/141 promotes ZEB1/2 expression and gastric cancer progression , 2014, Medical Oncology.

[30]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.